


Xeltis announces positive data for Xabg, its coronary artery bypass conduit, in EU clinical trial
Preliminary clinical data from Xabg, Xeltis’ coronary artery…

One Biosciences Announces €15 Million Series A Financing to Advance Clinical Single Cell Profiling
Funding will be used to establish the clinical utility of…

Heidelberg Pharma Reports on First Half-Year 2025 and the Positive Course of Business
Clinical trial with ATAC candidate HDP-101 in multiple myeloma…

Actithera Raises $75.5M in Oversubscribed Series A Financing to Redefine Precision Radioligand Therapy
Series A co-led by founding investor M Ventures and new lead…

Neuraxpharm and Dizlin Pharmaceuticals Announce Global Strategic Co-Development Agreement Bringing Next-Generation Drug-Device Therapy to Patients with Advanced Parkinson’s Disease
Infudopa SubC® is a user-friendly and minimally invasive alternative…

Jacob Falck Hansen appointed as Chief Executive Officer of Vesper Bio
Copenhagen, Denmark, 01 July 2025 – Vesper Bio ApS (“Vesper”…

Challenge accepted: New funding for ambitious projects within biomanufacturing, cardiometabolic diseases, and artificial intelligence
The 2025 Novo Nordisk Foundation Challenge Programme awards DKK…

STORM Therapeutics Appoints Veteran Cancer Drug Developer Dr. Eric Martin as Chief Development Officer
26 June 2025, Cambridge, UK: STORM Therapeutics Ltd. (STORM),…

Curve Therapeutics Co-Founder and CSO Professor Ali Tavassoli awarded the Royal Society of Chemistry’s Interdisciplinary Prize
Awarded in recognition of excellence in research and innovation…

New Danish research centre to make designed proteins with vast potential
Designed proteins are anticipated to have groundbreaking impact…

Breye Therapeutics announces successful completion of its Phase 1b trial with danegaptide in patients with diabetic retinopathy
Orally administered treatment was well tolerated, with early…

Atrogi announces Cell paper highlighting transformative potential of muscle-targeted therapy in metabolic disease
Atrogi’s breakthrough discovery enables chronic use of…

Rewind Therapeutics Strengthens Scientific Advisory Board with Leading International Neurology Experts as it Advances First-in-Class Remyelination Therapy
Professors Shiv Saidha, Cristina Granziera, David Leppert,…

Sofinnova Partners collaborates with NVIDIA to accelerate European life sciences startups
Delivers high-performing AI infrastructure through NVIDIA…

SpliceBio Secures $135 Million Series B Financing to Advance Lead Program SB-007 in Stargardt Disease and Expand Pipeline of Genetic Medicines
Financing co-led by new investors EQT Life Sciences and Sanofi…
We’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
We are specialists with an indepth understanding of how to communicate complex science to investors and corporate stakeholders. We help companies on their journey as they grow and have been trusted by hundreds of clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York